Aurigene’s biotech pipeline

IMMUNONCOLOGY

DISCOVERY

LEAD OP

PRECLINICAL

IND

PHASE I

82%
PD-L1/VISTA (Small Molecule)
TIM-3/PD1 61%
PD-L1/TIM-3
Immun platform 1%
Immunoncology Platform (Peptide/Peptidomimetics)
CD47 (Peptide) 1%
CD47 (Peptide)

PRECISION ONCOLOGY

IRAK4 75%
IRAK4
NAMPT 75%
NAMPT
KRAS 66%
KRAS
CDK7 65%
CDK7

EPIGENETICS

BET Bromodomain 80%
BET Bromodomain
PRMT5 1%
PRMT5
CREBBP 1%
CBP/P300
Menin-MLL 1%
Menin-MLL

INFLAMMATION

ROR Inverse Agonist 75%
ROR Inverse Agonist

key